EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Vector Pharma FZCO of Dubai UAE, the leading full-service distributor for rare disease, oncology and highly specialized therapeutics in the Middle East, North Africa and Turkish markets, announced a strategic partnership to expand services across the Middle East and North African markets.
GSK’s strong Q1 driven by COVID-19, returning demand for shingles vaccine
Antibodies, Business, Business Intelligence, Consumer Health Care, Consumer Healthcare, Coronavirus Disease 2019 (COVID-19), Earnings per share (EPS), Financials, GlaxoSmithKline, Guidance, Leadership, Operations, Presentations, Quarterly results, Sales, Sales, Sales & Marketing, Sales Guidance, Shingles, Strikes, Therapeutics, VaccinesGlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Pharmacy chain Walgreens Boots Alliance and other defendants on April 26 said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.
Johnson & Johnson filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of the company’s HIV drugs, months after a similar case brought by Gilead Sciences Inc.
Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8 percent, mostly outside of the United States. Sales for the generics and biosimilar unit benefited from what the company called a normalization of the impacts of COVID-19.
Walgreens Boots Alliance and Teva Pharmaceutical Industries Ltd. ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on April 25 during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
Walgreens, Teva face San Francisco trial over opioid epidemic
Alabama, AmerisourceBergen, Business, California, Cardinal Health, Drug Distributors, Endo, Epidemics, Johnson & Johnson, Lawsuits, Lawsuits, Los Angeles, McKesson, Opioid Lawsuits, Opioids, Opioids, Pharmacies, Pharmacy, Purdue Pharma, San Francisco, Therapeutics, U.S. Opioid Crisis, Walgreens Boots Alliance, West VirginiaSan Francisco squared off on April 25 against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
British employees of pharma giant GlaxoSmithKline voted to strike against the company’s recent pay raise. Hundreds of GSK workers backed by British labor union Unite demanded a higher raise, citing major inflation rates and the company’s recent financial successes.
CureVac, GSK’s experimental COVID variant vaccine effective in mice – study
B.1.1.7 "Kent" strain (United Kingdom), B.1.1.7 Variant (UK), B.1.621 or “Mu” variant (Colombia), BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 Variant B.1.1.7, COVID-19 Variant B.1.526 (New York), CureVac, Delta Subtype AY.4.2, Delta Variant (B.1.617.2; India), GlaxoSmithKline, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Omicron BA.2, Pandemics, R&D, TherapeuticsCureVac and GSK’s second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as the biotech firm seeks to catch up with rivals’ development work.
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.